Last reviewed · How we verify
GW117 Tablets
GW117 Tablets' mechanism of action is not publicly available.
At a glance
| Generic name | GW117 Tablets |
|---|---|
| Sponsor | Beijing Greatway Pharmaceutical Technology Co.,Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy Subjects (PHASE1)
- A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW117 Tablets CI brief — competitive landscape report
- GW117 Tablets updates RSS · CI watch RSS
- Beijing Greatway Pharmaceutical Technology Co.,Ltd. portfolio CI